AbbVie has announced its agreement to acquire Aliada Therapeutics, a company specializing in drug delivery technology for neurological disorders, for $1.4 billion in cash.
The acquisition of Aliada Therapeutics by AbbVie underscores the company's commitment to enhancing its capabilities in the neuroscience field. Aliada Therapeutics has developed a unique technology aimed at overcoming the blood-brain barrier, a significant challenge in the development of brain therapies. AbbVie's acquisition of Aliada provides access to this innovative technology and positions the company to advance its research and development efforts in neuroscience.
The technology developed by Aliada functions similarly to a Trojan horse, allowing potential therapeutic agents to be delivered effectively to the nervous system. This method is expected to enhance the efficacy of treatments for various neurological disorders.
AbbVie gains access to Aliada's clinical-stage Alzheimer's drug, ALIA-1758, which targets a specific form of amyloid beta proteins associated with the disease. This drug is currently undergoing a small study involving healthy volunteers.
The acquisition of Aliada Therapeutics is part of AbbVie's strategy to expand its portfolio through targeted acquisitions. AbbVie's commitment to neuroscience is reflected in its financial performance, with net revenue from its neuroscience products reaching $4.1 billion in the first half of the year.